Page last updated: 2024-11-06

gamma-bisabolene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID3033866
CHEBI ID49238
CHEBI ID49237
MeSH IDM0499026

Synonyms (45)

Synonym
cis-.gamma.-bisabolene
(z)-.gamma.-bisabolene
cyclohexene, 4-(1,5-dimethyl-4-hexenylidene)-1-methyl-
bisabolene (natural)
fema no. 3331
2-heptene, 2-methyl-6-(4-methyl-3-cyclohexen-1-ylidene)-
einecs 207-805-8
limene
2-methyl-6-(4-methyl-3-cyclohexen-1-ylidene)-2-heptene
4-(1,5-dimethylhex-4-en-1-ylidene)-1-methylcyclohexene
(1z)-bisabola-1(10),4,7(11)-triene
CHEBI:49238 ,
gamma-bisabolen
gamma-bisabolene
CHEBI:49237
bisabola-1(10),4,7(11)-triene
(z)-gamma-bisabolene
4-(1,5-dimethyl-4-hexenylidene)-1-methylcyclohexene
1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene
(4z)-4-(1,5-dimethylhex-4-en-1-ylidene)-1-methylcyclohexene
B1413
(z) gamma-bisabolene
(4z)-1-methyl-4-(6-methylhept-5-en-2-ylidene)cyclohexene
(1z)-bisabola-1(10),4,7(11)-triene (4z)-4-(1,5-dimethylhex-4-en-1-ylidene)-1-methylcyclohexene
LMPR0103060004
cyclohexene, 4-(1,5-dimethyl-4-hexen-1-ylidene)-1-methyl-
e6941s3u3q ,
unii-e6941s3u3q
unii-e452k502k0
e452k502k0 ,
gamma-bisabolene, (z)-
2-heptene, 2-methyl-6-(4-methyl-3-cyclohexen-1-ylidene)-, (z)-
cyclohexene, 4-(1,5-dimethyl-4-hexen-1-ylidene)-1-methyl-, (4z)-
gamma-bisabolene, (4z)-
cyclohexene, 4-(1,5-dimethyl-4-hexenylidene)-1-methyl-, (z)-
cis-gamma-bisabolene
13062-00-5
cyclohexene, 4-(1,5-dimethyl-4-hexenylidene)-1-methyl-, (4z)-
.gamma.-bisabolene, (4z)-
.gamma.-bisabolene, (z)-
AKOS024287123
(z)-1-methyl-4-(6-methylhept-5-en-2-ylidene)cyclohex-1-ene
Q4039091
DTXSID901037003
(4z)-1-methyl-4-(6-methyl-5-hepten-2-ylidene)cyclohexene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
gamma-bisabolene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]